Table 4.

Cox's proportional hazard model in the EGFR-positive patients (erlotinib, n = 78; placebo, n = 49)

AnalysesHR (95% CI)P*
Treatment only0.646 (0.430-0.969)0.0333
Prerandomization stratification factors (4)0.607 (0.401-0.918)0.018
Factors imbalanced between erlotinib and placebo (6)0.609 (0.400-0.927)0.0205
  • Abbreviations: CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.

  • * P value not adjusted for multiplicity.

  • Prior response (CR/PR versus SD/PD).

  • Factors imbalanced between erlotinib and placebo: baseline ECOG performance status (0-1 versus 2-3), response to prior therapy (CR/PR versus SD/PD), number of prior regimens (1 versus 2), age (≤60 versus >60), sex, and histology (adenocarcinoma versus others).